Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article synthesizes current evidence regarding psychedelics' effects on nature relatedness and social connectedness, examining underlying mechanisms through the framework of self-other overlap. Psychedelics appear to facilitate self-expansion through two complementary mechanisms: ego dissolution, which temporarily alters self-boundaries, and enhanced emotional processing, which increases empathic concern. While studies demonstrate promising effects, interpretation is complicated by methodological challenges including functional unblinding, reliance on self-reports, and small sample sizes. We propose a multidimensional model of connectedness that distinguishes between perceptual, emotional, and epistemic domains, each showing distinct patterns in acute and enduring effects. Future research would benefit from behavioral measures, active placebos, and careful consideration of contextual factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.copsyc.2025.101992 | DOI Listing |
Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article synthesizes current evidence regarding psychedelics' effects on nature relatedness and social connectedness, examining underlying mechanisms through the framework of self-other overlap. Psychedelics appear to facilitate self-expansion through two complementary mechanisms: ego dissolution, which temporarily alters self-boundaries, and enhanced emotional processing, which increases empathic concern.
View Article and Find Full Text PDFEClinicalMedicine
October 2024
Centre for Psychedelic Research, Division of Psychiatry, Department Brain Sciences, Imperial College London, United Kingdom.
Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.
Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.
Sci Rep
December 2024
Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
Psychoactive drugs such as alcohol and stimulants are typically used in social settings such as bars, parties or small groups. Yet, relatively little is known about how social contexts affect responses to drugs, or how the drugs alter social interactions. It is possible that positive social contexts enhance the rewarding properties of drugs, perhaps increasing their potential for repeated use and abuse.
View Article and Find Full Text PDFSociol Health Illn
January 2025
Community & Behavioral Health and the Department of Sociology, State University of New York (SUNY) Polytechnic Institute, Utica, New York, USA.
There is a disparity between contemporary scientific investigations into psychedelic phenomena and their 20-century counterparts, notably the lack of examination of psychedelic experiences within group settings. Whereas early research studies from the 1950s to the 1970s explored communal settings in psychedelic-assisted therapy (PAT), today's resurgence of scholarship in the field primarily considers individualised, often clinical, settings. Consequently, there is an absence of empirical research and theoretical innovation on collective psychedelic contexts, for example, how social connectedness occurs relationally and what its impacts are.
View Article and Find Full Text PDFTrials
May 2024
Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Waikato Clinical Campus, Peter Rothwell Academic Centre, Pembroke Street, Hamilton, 3240, New Zealand.
Background: Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in this population. Several centres have reported that one dose of the serotonergic psychedelic psilocybin, combined with therapeutic support, improves these symptoms for up to 6 months in this patient group. Drawing upon related therapeutic mechanisms, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy may have the potential to achieve similar, positive mental health outcomes in this group.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!